Limits...
Managing patients with ICD shocks and programming tachycardia therapies during acute heart failure syndromes.

Bradfield J, Tung R, Boyle NG, Shivkumar K - Heart Fail Rev (2011)

Bottom Line: We review the pharmacologic, interventional and device programming treatment options for patients with implantable cardioverter-defibrillators who present with acute heart failure and implantable cardioverter-defibrillator shocks.

View Article: PubMed Central - PubMed

Affiliation: UCLA Cardiac Arrhythmia Center, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine at UCLA, A2-237 CHS, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1679, USA. JBradfield@mednet.ucla.edu

ABSTRACT
We review the pharmacologic, interventional and device programming treatment options for patients with implantable cardioverter-defibrillators who present with acute heart failure and implantable cardioverter-defibrillator shocks.

Show MeSH

Related in: MedlinePlus

Combined endocardial and epicardial mapping (left) of nonischemic substrate presenting with VT storm. Red dots on epicardial map (right) created with CARTO electroanatomical mapping system (Biosense Webster, Diamond Bar, CA) represent ablation lesions at the site of origin of VT
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3139863&req=5

Fig2: Combined endocardial and epicardial mapping (left) of nonischemic substrate presenting with VT storm. Red dots on epicardial map (right) created with CARTO electroanatomical mapping system (Biosense Webster, Diamond Bar, CA) represent ablation lesions at the site of origin of VT

Mentions: It should be recognized that prolonged ablation procedures in the setting of acute heart failure may substantially increase peri-procedural risks due to prolonged supine position, protracted anesthesia, and potential volume loading associated with externally irrigated ablation catheters. Therefore, optimization of volume status is essential prior to consideration for VT ablation. In patients with electrical storm which persists despite aggressive management of acute heart failure and antiarrhythmic drug therapy, substrate-based ablation of unstable VT in sinus rhythm guided by electroanatomic mapping systems has been demonstrated to be effective for preventing arrhythmic recurrence [44, 45] (Fig. 2).Fig. 2


Managing patients with ICD shocks and programming tachycardia therapies during acute heart failure syndromes.

Bradfield J, Tung R, Boyle NG, Shivkumar K - Heart Fail Rev (2011)

Combined endocardial and epicardial mapping (left) of nonischemic substrate presenting with VT storm. Red dots on epicardial map (right) created with CARTO electroanatomical mapping system (Biosense Webster, Diamond Bar, CA) represent ablation lesions at the site of origin of VT
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3139863&req=5

Fig2: Combined endocardial and epicardial mapping (left) of nonischemic substrate presenting with VT storm. Red dots on epicardial map (right) created with CARTO electroanatomical mapping system (Biosense Webster, Diamond Bar, CA) represent ablation lesions at the site of origin of VT
Mentions: It should be recognized that prolonged ablation procedures in the setting of acute heart failure may substantially increase peri-procedural risks due to prolonged supine position, protracted anesthesia, and potential volume loading associated with externally irrigated ablation catheters. Therefore, optimization of volume status is essential prior to consideration for VT ablation. In patients with electrical storm which persists despite aggressive management of acute heart failure and antiarrhythmic drug therapy, substrate-based ablation of unstable VT in sinus rhythm guided by electroanatomic mapping systems has been demonstrated to be effective for preventing arrhythmic recurrence [44, 45] (Fig. 2).Fig. 2

Bottom Line: We review the pharmacologic, interventional and device programming treatment options for patients with implantable cardioverter-defibrillators who present with acute heart failure and implantable cardioverter-defibrillator shocks.

View Article: PubMed Central - PubMed

Affiliation: UCLA Cardiac Arrhythmia Center, Ronald Reagan UCLA Medical Center, David Geffen School of Medicine at UCLA, A2-237 CHS, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1679, USA. JBradfield@mednet.ucla.edu

ABSTRACT
We review the pharmacologic, interventional and device programming treatment options for patients with implantable cardioverter-defibrillators who present with acute heart failure and implantable cardioverter-defibrillator shocks.

Show MeSH
Related in: MedlinePlus